Bruno Sarmento among the most influential specialists in Biomedical Engineering
Bruno Sarmento, a researcher at i3S, was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE), one of the most relevant international distinctions in the field of biomedical engineering.
This election recognises high-impact scientific contributions to the development of therapeutic nanotechnologies, advanced drug delivery systems, and innovative translational approaches for the administration of biomolecules.
The induction ceremony will take place during the AIMBE Annual Event, which will be held from the 11th to the 13th of April 2026 in Washington, D.C., in the United States of America (USA). On this occasion, the researcher will formally join the College of Fellows, which is composed of around three thousand scientific leaders, engineers, entrepreneurs, and innovators who have distinguished themselves through significant advances in medical and biological engineering.
“Being elected a Fellow of AIMBE constitutes a recognition of great relevance in my career,” the researcher states. “This result was only possible thanks to the extraordinary work of the members of my research group, who contribute daily to maintaining a very high level of scientific excellence. It is also a recognition that I share entirely with my family, whose unconditional support is essential for coordinating scientific activity with family life,” Bruno Sarmento adds.
A year marked by scientific excellence and international leadership
The election to AIMBE has occurred during an especially significant period for the researcher and for the Nanomedicines & Translational Drug Delivery research group, which has demonstrated highly competitive scientific indicators of innovation and funding capture.
The group’s scientific performance has been widely recognised internationally, consolidating i3S as an emerging reference in the field of nanomedicine and drug delivery systems.
This moment of affirmation coincides with another important milestone in Bruno Sarmento’s career. In July 2026, during the annual congress of the Controlled Release Society (CRS) to be held in Lisbon, he will begin his term as President of the society, one of the world’s most influential organisations dedicated to controlled drug release technologies.
Strategic impact of AIMBE
AIMBE, founded in 1991, promotes public policies based on scientific evidence, stimulates biomedical innovation, and provides strategic recommendations to the North American research and health ecosystem.
The integration of Bruno Sarmento into this college reinforces the presence of Portuguese research in international debates critical to the future of bioengineering and translational medicine. He will be the third Portuguese researcher to join this select group, creating new opportunities for institutional, scientific, and technological collaboration.
Strengthening scientific links between Portugal and the USA will be one of the researcher’s priorities. “We have a highly qualified scientific community and infrastructures of excellence, and the USA presents a robust biomedical ecosystem oriented towards translational innovation,” he notes. “AIMBE is the ideal space to strengthen these connections, especially at this time of increased challenges for the American scientific community,” the researcher concludes.
